ClinicalTrials.gg
Not yet recruitingNCT06117124Updated Mar 25, 2025

The BoDI (Bone Density Investigation) Study

An interventional study of Digital X-Ray Radiogrammetry and Quantitative Ultrasound (QUS) in Cerebral Palsy, sponsored by Sussex Community NHS Foundation Trust. Not yet recruiting. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-25.

Sponsored by Sussex Community NHS Foundation Trust · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

Background:

This study involves children with cerebral palsy, a lifelong condition caused by early damage to the developing brain.

This condition is associated with impairments in mobility and motor control, eating and drinking, communication and learning, as well as other physical health difficulties. Included in these is a risk of developing osteoporosis, that is thin, weakened bones which are more prone to fracture.

Currently there is no clear guidance for how bone density should be measured or monitored in this vulnerable group of children. The recommended imaging method in children, dual energy x-ray absorptiometry (DEXA) has specific and significant limitations in children with cerebral palsy.

Aim:

This study aims to investigate two alternative methods of measuring bone density, quantitative ultrasound and digital x-ray radiogrammetry. The former uses ultrasound to measure the strength and elasticity of bone, while the latter uses hand x-rays to calculate bone density. It aims to explore the reliability, acceptability and clinical utility of both methods, as well as the correlation between the two methods. Risk factors and the clinical course of the disease will also be explored.

Method:

The study aims to recruit 70 children and young people aged 3-18 years with cerebral palsy. Participants will undergo both methods of bone density measurement twice over a 12-month period. Information on clinical risk factors and fracture rate will be taken from clinical records.

Read the detailed description

Osteoporosis is a condition in which bone strength and structure is altered, so that it is more likely to break or fracture. It is a condition that has been traditionally associated with age, with women of a post-menopausal age particularly at risk. However, poor bone strength (or medically termed 'bone density') is increasingly recognised in children suffering from chronic health conditions. It is usually caused by a combination of the disease process itself, as well as the treatments and consequences of the disease.

Where childhood is usually the critical period in which bone strength is developed (and 'bone mass' accrued), these at-risk children enter adulthood with much weaker bones and at much higher ongoing risk of fracture. To minimise this risk in adulthood, the core difficulty with bone strength in childhood needs to be addressed. Of all childhood chronic health conditions, cerebral palsy is the most common condition associated with low bone density. It affects 2.7 in 1000 births and is increasing in incidence due to the increased survival of low-birth-weight infants. Low bone density is universal in children with moderate to severe Cerebral Palsy after the age of 10 years, and up to a quarter of these children will present with low-impact fractures. These are associated with pain, loss of function and quality of life, as well as significant complications, and they currently represent the most common medical problem seen in children with cerebral palsy attending residential schools.

There is currently no clear guidance for this population of at-risk children with regards to the appropriate method or timing of bone density screening. In addition, while Dual energy x-ray absorptiometry (DEXA) is currently the recommended method for measurement of bone density in children and adolescents, it has a number of limitations specifically in children with cerebral palsy. These include difficulties with accessing appropriate scanners, challenges regarding positioning and movement during scanning, and other challenges such as metallic implants from spinal and hip surgeries impacting on the ability to achieve accurate results. There is an increasing interest therefore in alternative methods of measuring bone strength in children. In 2021, a systematic review paper analysed 22 studies comparing alternative methods to DEXA in children; it concluded that quantitative ultrasound and digital x-ray radiogrammetry were both reliable methods that warrant further investigation. Of note, none of the included studies focused on children with cerebral palsy.

This study would be the first to investigate the use of these two alternative methods in children with cerebral palsy. It will address the important question of whether there is a role for these potentially more acceptable methods in screening for low bone density and predicting future fracture risk. It will also align with the research priority set by the James Lind Alliance in 2022 of managing 'distressing symptoms such as pain' in children with neurological conditions.

The aim of this study is to compare quantitative ultrasound and digital x-ray radiogrammetry as alternative and more suitable methods of bone densitometry in children with cerebral palsy.

The primary objectives of the study are:

  • To compare agreement between the two densitometry techniques in children with Cerebral Palsy
  • To investigate the correlation between assessments using both techniques and clinical information/ risk factors for low bone density in children with Cerebral Palsy

The secondary objectives of the study are:

  • To compare bone density changes over time and identify the most appropriate timing and site of bone density screening in children with Cerebral Palsy
  • To establish the risk factors associated with low bone density and pathological (low impact) fracture in this at-risk group of children
  • To compare intra- and interobserver variability for both methods: that is, how consistent the results are when the investigation is performed on the same patient by the same practitioner, and on the same patient by a different practitioner.
  • To compare the practicality of both methods (from the participant and practitioner viewpoint) and the cost-effectiveness of both methods
  • To devise a large multi-centre trial comparing the superior of the two methods to DEXA scanning.
02

Conditions studied

  • Cerebral Palsy

Browse trials for

03

In context

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

This study's planned enrollment of 70 is above the median of 34 across 1,434 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Sussex Community NHS Foundation Trust is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 3-18 years of age (male and female)
  • Diagnosis of mild to severe cerebral palsy (Gross Motor Function Classification System Level 1 to 5)

Exclusion criteria

Exclusion Criteria:

  • Progressive or other neurological condition not diagnostic of Cerebral Palsy
  • Previous treatment with bisphosphonates or other bone density modifying medications (aside from nutritional supplements)
  • Other underlying conditions associated with low bone density e.g. or inflammatory conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Quantitative ultrasound

    Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.

    Radiation: Digital X-Ray Radiogrammetry · Diagnostic Test: Quantitative Ultrasound (QUS)

  • Active comparator
    Digital x-ray radiogrammetry.

    Participants will undergo bone density measurement using two different modalities - quantitative ultrasound and digital x-ray radiogrammetry. Each method will be performed twice over a 12 month period, to assess changes in bone density over time.

    Radiation: Digital X-Ray Radiogrammetry · Diagnostic Test: Quantitative Ultrasound (QUS)

Interventions

  • RadiationDigital X-Ray Radiogrammetry

    An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.

  • Diagnostic testQuantitative Ultrasound (QUS)

    The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.

06

What researchers measure

Primary outcomes

  1. Measures taken by two densitometry techniques (quantitative ultrasound and digital x-ray radiogrammetry)

    Level of agreement between the two techniques and correlation of both techniques with clinical findings

    Time frame: 12 months

Secondary outcomes

  1. Bone density changes over time

    - assess bone density changes over time and identify the most appropriate timing and site of bone density screening

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jan 2029, 41 months later.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 41 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Nov 3, 2023
StartEst.
Aug 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Mar 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117124
Lead sponsor
Sussex Community NHS Foundation Trust
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Aug 2025 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion